Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Joycelyn Tan, a Ph.D. student at the Wellcome-MRC Institute of Metabolic Science at the University of Cambridge, UK, has been awarded the 2024 Darlene Solomon Award. The award recognizes and supports promising female scientists working in mass spectrometry. Ms. Tan is a member of the Fazakerley group, which is dedicated to understanding the mechanisms responsible for obesity and related metabolic dise.

Agilent Presents 2024 Darlene Solomon Award to University of Cambridge Researcher Joycelyn Tan

Agilent Technologies, Inc. (NYSE:A ) 44th Annual TD Cowen Health Care Conference March 4, 2024 2:50 PM ET Company Participants Robert McMahon - SVP and CFO Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Here to kick off the Agilent session.

Agilent Technologies, Inc. (A) Presents at 44th Annual TD Cowen Health Care Conference (Transcript)

Agilent's (A) first-quarter fiscal 2024 results reflect softness across the LSAG and DGG segments. Weak momentum in China has been concerning.

Agilent (A) Q1 Earnings & Revenues Beat Estimates, Dip Y/Y

Shares in Agilent Technologies (A) gained nearly 5% in Tuesday's extended-hours trading session after the laboratory supplies maker topped analysts' quarterly top- and bottom-line expectations, despite sales contracting from the prior year.

Agilent Technologies Stock Jumps As Earnings Top Estimates—Key Levels to Watch

Agilent Technologies, Inc. (A) Q1 2024 Earnings Call Transcript

The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended January 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Agilent (A) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Agilent Technologies on Tuesday beat Wall Street estimates for first-quarter profit and revenue, helped by strong sales in its life sciences and diagnostics units, sending shares up 5% in extended trading.

Agilent reports better-than-expected first quarter results, shares rise

Agilent Technologies (A) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.37 per share a year ago.

Agilent Technologies (A) Beats Q1 Earnings and Revenue Estimates

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the first quarter ended Jan. 31, 2024, a decline of 5.6% reported and 6.4% core(1) compared to the first quarter of 2023. First-quarter GAAP net income was $348 million, or $1.18 per share. This compares with $352 million, or $1.19 per share, in the first quarter of fiscal year 2023. Non-GAAP(2) net income was $380 million, or $1.29 per share during the quarter, compared with $4.

Agilent Reports First-Quarter Fiscal Year 2024 Financial Results

LendingTree

Urban Outfitters

With representation from a variety of sectors, several top-rated Zacks stocks look attractive ahead of their quarterly reports on Tuesday, February 27.

3 Top-Rated Stocks to Consider as Earnings Approach

Agilent's (A) results for the fiscal first quarter are expected to reflect strength across ACG amid weakness in the LSAG and DGG segments.

Agilent Technologies (A) to Post Q1 Earnings: What's in Store?

Remitly Global

Remitly Global, Inc. (RELY) Q4 2023 Earnings Call Transcript

Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended January 2024.

Agilent (A) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Padraig McDonnell, president of the Agilent CrossLab Group (ACG), has been named CEO-elect and chief operating officer (COO) of the company, succeeding current President and CEO Mike McMullen who will retire. McDonnell will become Agilent's president and CEO and join Agilent's Board of Directors on May 1. After nearly 40 years with Agilent and its predecessor Hewlett-Packard Co., McMullen will continu.

Agilent CEO Mike McMullen to Retire; Agilent CrossLab Group President Padraig McDonnell Named CEO-Elect

Agilent Technologies (A) reachead $132.24 at the closing of the latest trading day, reflecting a +1.91% change compared to its last close.

Agilent Technologies (A) Surpasses Market Returns: Some Facts Worth Knowing

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company was again named one of the Most JUST Companies in America by Just Capital and CNBC. This marks the sixth year Agilent has appeared on the exclusive list, and the fourth year the company has ranked in the top 50. The list highlights 100 companies that are performing best on business issues that matter most to the U.S. public, from paying a living wage and creating jobs to prioritizing accountabi.

Agilent Ranked Among Top 50 Most Just Companies in America

Biogen

Bristol-Myers

C.H. Robinson Worldwide

Core Laboratories Inc

Comcast

Compass Minerals

Campbell Soup

Corteva Inc

Estee Lauder

Etsy

Gilead Sciences

Huntington Ingalls Industries

Hilton Worldwide Holdings

Harley-Davidson

Honeywell

International Flavors & Fragrances

InterContinental Hotels Group

Kenvue

Lockheed Martin

Marriott

McDonald's

MarketAxess Holdings

Altria

NIKE

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

U.S. Wide-Moat Stocks On Sale - The February 2024 Heat Map

In the most recent trading session, Agilent Technologies (A) closed at $134.07, indicating a +0.96% shift from the previous trading day.

Agilent Technologies (A) Outperforms Broader Market: What You Need to Know

SANTA CLARA, Calif.--(BUSINESS WIRE)--Scientists' Choice Awards highlight Agilent's commitment to innovation and excellence in drug discovery and development.

Agilent Wins Two Scientists' Choice Awards for Drug Discovery and Development Products

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CFO Bob McMahon will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston, Massachusetts, on Monday, March 4, at 2:50 p.m. EST. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tech.

Agilent to Participate in TD Cowen Health Care Conference

Agilent Technologies (A) concluded the recent trading session at $132.97, signifying a -0.06% move from its prior day's close.

Agilent Technologies (A) Stock Slides as Market Rises: Facts to Know Before You Trade

Fortive

Investors with an interest in Electronics - Testing Equipment stocks have likely encountered both Fortive (FTV) and Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?

FTV vs. A: Which Stock Is the Better Value Option?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent's expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte's hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030,1 driven in part by the power of these tests to inform treatment decisions.

Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology

In the latest trading session, Agilent Technologies (A) closed at $130.99, marking a +0.85% move from the previous day.

Agilent Technologies (A) Advances While Market Declines: Some Information for Investors

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2024 after the stock market closes on Tuesday, Feb. 27. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call will also be available on the website for 90 days. About.

News for Agilent Technologies Stock (A)